- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: CEP37440  | compound 27b [PMID: 27527804]
Compound class: Synthetic organic
Comment: CEP-37440 is an orally available, dual focal adhesion kinase (FAK) and anaplastic lymphoma kinase (ALK) inhibitor . The chemical structure is claimed in patent US20170369451 . The compound is an oncology lead candidate .
Note that this entry has been updated to reflect an error in the article that initially attributed this chemical structure to the compound BMS-986165 (online corrected article , erratum described in ). The structure of BMS-986165 has not in fact been disclosed.
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
|No information available.|
|Summary of Clinical Use|
|CEP-37440 has completed Phase 1 clinical trial as an oncology candidate (see NCT01922752).|
|Clinical Trial ID||Title||Type||Source||Comment||References|
|NCT01922752||To Determine the Maximum Tolerated Dose of Oral CEP-37440 in Patients With Advanced or Metastatic Solid Tumors||Phase 1 Interventional||Teva Pharmaceutical Industries|